STAAR Surgical Company (STAA) Getting Favorable Press Coverage, Analysis Finds

Headlines about STAAR Surgical Company (NASDAQ:STAA) have trended positive this week, according to AlphaOne Sentiment Analysis. The research firm, a division of Accern, scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. STAAR Surgical Company earned a news impact score of 0.40 on AlphaOne’s scale. AlphaOne also gave media headlines about the medical instruments supplier an impact score of 30 out of 100, indicating that recent media coverage is unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have impacted AlphaOne’s analysis:

Insider Buying and Selling by Quarter for STAAR Surgical Company (NASDAQ:STAA)

Shares of STAAR Surgical Company (NASDAQ:STAA) traded down 1.03% during midday trading on Friday, hitting $9.60. The stock had a trading volume of 140,151 shares. The firm’s market cap is $392.95 million. The firm has a 50-day moving average of $9.65 and a 200 day moving average of $10.05. STAAR Surgical Company has a 12-month low of $5.12 and a 12-month high of $11.50.

STAAR Surgical Company (NASDAQ:STAA) last announced its earnings results on Wednesday, May 3rd. The medical instruments supplier reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). STAAR Surgical Company had a negative return on equity of 10.83% and a negative net margin of 7.53%. The firm had revenue of $20.35 million during the quarter. During the same quarter in the previous year, the company earned ($0.20) EPS. On average, analysts expect that STAAR Surgical Company will post ($0.15) earnings per share for the current year.

Several equities research analysts have issued reports on the company. Canaccord Genuity restated a “hold” rating and set a $9.00 price objective on shares of STAAR Surgical Company in a report on Friday, March 3rd. Benchmark Co. restated a “buy” rating and set a $12.00 price objective (up from $10.00) on shares of STAAR Surgical Company in a report on Friday, March 3rd. Finally, Zacks Investment Research downgraded STAAR Surgical Company from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th.

WARNING: “STAAR Surgical Company (STAA) Getting Favorable Press Coverage, Analysis Finds” was posted by sleekmoney and is the property of of sleekmoney. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at

About STAAR Surgical Company

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *